title: [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
abstract: Treatment with anti-tumor necrosis factor (TNF)-α for Crohn's disease is relatively safe, although various cutaneous adverse effects have been reported such as the development or exacerbation of anti-TNF- α-induced psoriasis, which can sometimes lead to treatment withdrawal. Therefore, new alternative treatments with new mechanisms of action are required. Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin 12/23, could induce response in patients with Crohn's disease and has demonstrated efficacy in patients with psoriasis. We present the case of a woman with Crohn's disease who developed psoriasis after treatment with two anti-TNF- α drugs (infliximab and adalimumab). The patient was subsequently treated with ustekinumab with resolution or psoriasis lesions and maintenance of remission of Crohn's disease.
authors.affiliation: Servicio de Digestivo, Hospital de Manacor, Manacor, Baleares, España. asanso@hospitalmanacor.org
authors.forename: Andrés
authors.initials: A
authors.lastname: Sansó Sureda
authors.forename: Vicenç
authors.initials: V
authors.lastname: Rocamora Durán
authors.forename: Amparo
authors.initials: A
authors.lastname: Sapiña Camaró
authors.forename: Vanesa
authors.initials: V
authors.lastname: Royo Escosa
authors.forename: María José
authors.initials: MJ
authors.lastname: Bosque López
mesh_terms: D000068879:Adalimumab; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D053762:Interleukin-12 Subunit p40 / Q000037:antagonists & inhibitors* / Q000276:immunology; D019804:Mesalamine / Q000008:administration & dosage / Q000627:therapeutic use; D010789:Phototherapy; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D000069549:Ustekinumab
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D053762:Interleukin-12 Subunit p40; D014409:Tumor Necrosis Factor-alpha; D019804:Mesalamine; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D001379:Azathioprine